Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
暂无分享,去创建一个
[1] G. Fuller,et al. PD-L1 expression and prognostic impact in glioblastoma. , 2016, Neuro-oncology.
[2] T. Fest,et al. Frequent expression of PD‐L1 on circulating breast cancer cells , 2015, Molecular oncology.
[3] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[4] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[5] D. Hafler,et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma , 2015, Nature Reviews Neurology.
[6] J. Wolchok. PD-1 Blockers , 2015, Cell.
[7] M. Weller,et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. , 2015, Neuro-oncology.
[8] D. Reardon,et al. Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. , 2015, Neuro-oncology.
[9] Jun Zhao,et al. Prognostic value of programed death ligand 1 in patients with solid tumors: A meta-analysis. , 2015, Journal of cancer research and therapeutics.
[10] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[11] R. David. PD-L1 expression by circulating breast cancer cells. , 2015, The Lancet. Oncology.
[12] Jian Huang,et al. PD-L1 and Survival in Solid Tumors: A Meta-Analysis , 2015, PloS one.
[13] Matteo Brunelli,et al. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers , 2015, PloS one.
[14] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[15] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[16] G. Ricken,et al. Tumour‐infiltrating lymphocytes and expression of programmed death ligand 1 (PD‐L1) in melanoma brain metastases , 2015, Histopathology.
[17] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[18] A. Heimberger,et al. Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege , 2014, Clinical Cancer Research.
[19] G. Reifenberger,et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.
[20] Y. Cheng,et al. Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors , 2014, Clinical Cancer Research.
[21] R. Gascoyne,et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. , 2013, Blood.
[22] Katie Kingwell. Neuro-oncology: Glioblastoma prognosis linked to neuronal PD-L1 expression in tumour-adjacent tissue , 2013, Nature Reviews Neurology.
[23] P. Siesjö,et al. PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients , 2013, The Journal of Neuroscience.
[24] Jiang Li,et al. Large Scale Comparison of Gene Expression Levels by Microarrays and RNAseq Using TCGA Data , 2013, PloS one.
[25] K. Aldape,et al. Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas , 2013, Cancer Immunology Research.
[26] John Wong,et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. , 2013, International journal of radiation oncology, biology, physics.
[27] R. Kaur,et al. Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages , 2013, Clinical Cancer Research.
[28] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[29] J. Ju,et al. A frequent somatic mutation in CD274 3′‐UTR leads to protein over‐expression in gastric cancer by disrupting miR‐570 binding , 2012, Human mutation.
[30] M. Weller,et al. Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness , 2011, Clinical Cancer Research.
[31] R. Stupp,et al. Current concepts and management of glioblastoma , 2011, Annals of neurology.
[32] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[33] J. Mosser,et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions , 2010, Journal of Neuroimmunology.
[34] Wei Keat Lim,et al. The transcriptional network for mesenchymal transformation of brain tumors , 2009, Nature.
[35] M. Wasik,et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) , 2008, Proceedings of the National Academy of Sciences.
[36] M. Weller,et al. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. , 2007, Neuro-oncology.
[37] D. Bigner,et al. Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function , 2007, Clinical Cancer Research.
[38] Thomas D. Wu,et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.
[39] A. Bar-Or,et al. Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS , 2005, The Journal of Neuroscience.
[40] M. Weller,et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. , 2003, Cancer research.
[41] Yoshimasa Tanaka,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[42] G. Freeman,et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.
[43] Alberto Mantovani,et al. Inflammation and cancer: back to Virchow? , 2001, The Lancet.
[44] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[45] S. Dzik. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion , 2000 .
[46] T. Honjo,et al. Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.
[47] J. Wolchok,et al. The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. , 2015, Advances in cancer research.
[48] G. Ricken,et al. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). , 2014, Clinical neuropathology.
[49] J. Uhm,et al. The transcriptional network for mesenchymal transformation of brain tumours , 2010 .
[50] P. Mischel,et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.